Vanguard Group Inc. recently reduced its stake in Merck & Co., Inc. by selling 777,516 shares, though it still holds over 252 million shares valued at approximately $21.16 billion. Merck has surpassed quarterly earnings expectations and provided optimistic FY2026 EPS guidance. While analysts largely rate the stock as a “Moderate Buy” with an average price target of $123.71, some company insiders have sold a significant number of shares in the past three months.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Vanguard Group Inc. Sells 777,516 Shares of Merck & Co., Inc. $MRK
Vanguard Group Inc. recently reduced its stake in Merck & Co., Inc. by selling 777,516 shares, though it still holds over 252 million shares valued at approximately $21.16 billion. Merck has surpassed quarterly earnings expectations and provided optimistic FY2026 EPS guidance. While analysts largely rate the stock as a “Moderate Buy” with an average price target of $123.71, some company insiders have sold a significant number of shares in the past three months.